Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2389-2394

  Laohavaleeson, Somvadee ^a   Tessier, Pamela R ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; EXPERIMENTAL INFECTION; FEMALE; LUNG LAVAGE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; METHICILLIN RESISTANCE; MICE; MICE, INBRED BALB C; PHENOTYPE; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS;

EID: 46249085997     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01422-07     Document Type: Article

References (31)

1. Adis International Data Information. 2006. Ceftobiprole medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. Drugs R. D. 7:305-311.
2. Andes, D. R., and W. A. Craig. 2000. In-vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens, abstr. 1079. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
3. Anonymous. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
4. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
5. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
6. Bush, K., M. Heep, M. J. Macielag, and G. J. Noel. 2007. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin. Investig. Drugs 16:419-429.
7. Capitano, B., D. Maglio, M. A. Banevicius, C. H. Nightingale, and D. P. Nicolau. 2003. Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model. Int. J. Antimicrob. Agents 22:588-593.
8. Centers for Disease Control and Prevention. 2007. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb. Mortal. Wkly. Rep. 56:325-329.
9. Chambers, H. F. 2006. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. 12(Suppl. 2):17-22.
10. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI publication M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
12. Deresinski, S. 2005. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40:562-573.
13. Deshpande, L., P. R. Rhomberg, T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary gram-positive and gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50:73-75.
14. Du, X., C. Li, H. K. Sun, C. H. Nightingale, and D. P. Nicolau. 2005. A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC. J. Pharm. Biomed. Anal. 39:648-652.
15. Francis, J. S., M. C. Doherty, U. Lopatin, C. P. Johnston, G. Sinha, T. Ross, M. Cai, N. N. Hansel, T. Perl, J. R. Ticehurst, K. Carroll, D. L. Thomas, E. Nuermberger, and J. G. Bartlett. 2005. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40:100-107.
16. Fridkin, S. K., J. C. Hageman, M. Morrison, L. T. Sanza, K. Como-Sabetti, J. A. Jernigan, K. Harriman, L. H. Harrison, R. Lynfield, and M. M. Farley. 2005. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436-1444.
17. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
18. Kollef, M. H., and S. T. Micek. 2006. Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen? Curr. Opin. Infect. Dis. 19: 161-168.
19. Kollef, M. H., A. Shorr, Y. P. Tabak, V. Gupta, L. Z. Liu, and R. S. Johannes. 2005. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128: 3854-3862.
20. Kowalski, T. J., E. F. Berbari, and D. R. Osmon. 2005. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin. Proc. 80:1201-1207.
21. Lange, N. R., and D. P. Schuster. 1999. The measurement of lung water. Crit. Care (London) 3:R19-R24.
22. LaPlante, K. L., M. J. Rybak, M. Amjad, and G. W. Kaatz. 2007. Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus. Pharmacotherapy 27:3-10.
23. Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, Jr., D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney. 2007. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2): S27-S72.
24. Mohr, J. F., and B. E. Murray. 2007. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44:1536-1542.
25. Nicolau, D. P., H. M. Mattoes, M. Banevicius, D. Xuan, and C. H. Nightingale. 2003. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob. Agents Chemother. 47:1630-1635.
26. Noel, G. J., R. S. Strauss, R. Pypstra, and the 00154 Study Group. 2006. Successful treatment of complicated skin infections (cSSSI) due to staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) with ceftobiprole, abstr. L-1212. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
27. Pea, F., and P. Viale. 2006. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis. 42:1764-1771.
28. Rouse, M. S., M. M. Hein, P. Anguita-Alonso, J. M. Steckelberg, and R. Patel. 2006. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55:333-336.
29. Tessier, P. R., M. K. Kim, W. Zhou, D. Xuan, C. Li, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1425-1434.
30. Zetola, N., J. S. Francis, E. L. Nuermberger, and W. R. Bishai. 2005. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect. Dis. 5:275-286.
31. Ziglam, H. M., D. R. Baldwin, I. Daniels, J. M. Andrew, and R. G. Finch. 2002. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50:1011-1015.